For decades, the cancer vaccine field carried a reputation for overpromising and underdelivering — Sipuleucel-T's 2010 approval stood as both a milestone and an endpoint, with no therapeutic successors following it to market. That stagnation may now be ending. The convergence of personalized mRNA technology with neoantigen profiling and AI-assisted target selection is reshaping what immunological targeting of tumors can realistically achieve.
This comprehensive review published in Signal Transduction and Targeted Therapy catalogs the current landscape of personalized cancer vaccine platforms — spanning DNA, mRNA, peptide, dendritic cell, and whole-cell approaches — and benchmarks the clinical momentum behind two leading mRNA candidates. Moderna's mRNA-4157 and BioNTech's autogene cevumeran have both demonstrated measurable reductions in cancer recurrence risk and improved survival signals across multiple tumor types in recent trial data. The review also details next-generation delivery architecture, including lipid-polymer hybrid nanovaccines and biomimetic membranes derived from autologous tumor cells, which enable simultaneous delivery of neoantigens alongside immune-stimulatory agonists — a design intended to overcome the immunosuppressive tumor microenvironment that has historically neutralized therapeutic cancer vaccines.
The practical significance here extends beyond oncology specialists. From a longevity and healthspan perspective, cancer remains one of the leading causes of premature mortality, and vaccines that could meaningfully extend disease-free intervals after initial treatment represent a genuine healthspan intervention. That said, this is a review article rather than a primary trial report, which means its strength lies in synthesis rather than new empirical data. The clinical evidence base for mRNA-4157 and autogene cevumeran, while promising, remains largely Phase II, with broader efficacy and durability data still maturing. Tumor heterogeneity and immune memory formation remain unresolved challenges. Still, the integration of AI-driven neoantigen selection with stimulus-responsive delivery systems marks this as a potentially paradigm-shifting moment rather than incremental progress — one worth monitoring closely as Phase III data emerge.